Japanese Journal of Ophthalmology

, Volume 57, Issue 5, pp 440–446 | Cite as

Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye

  • Shizuka Koh
  • Chikako Ikeda
  • Yoshihiro Takai
  • Hitoshi Watanabe
  • Naoyuki Maeda
  • Kohji Nishida
Clinical Investigation



To evaluate the preliminary long-term efficacy of diquafosol ophthalmic solution for aqueous-deficient dry eye.


Fifteen patients with mild-to-moderate aqueous-deficient dry eye were enrolled. After a washout period, the patients were treated with 3 % diquafosol ophthalmic solution for 6 months. We assessed 12 subjective dry eye symptoms, corneal and conjunctival staining with fluorescein, tear film break-up time (BUT), lower tear meniscus height measured with anterior-segment optical coherence tomography, Schirmer’s testing, and adverse reactions at baseline and 1, 3, and 6 months after the start of treatment.


Treatment with diquafosol ophthalmic solution significantly improved dry eye symptoms, corneal staining, BUT, and tear meniscus height at 1 month and maintained the effectiveness for 6 months. Conjunctival staining significantly improved 3 and 6 months after treatment. No significant adverse reactions developed.


Prolonged use of diquafosol ophthalmic solution for 6 months produced significant improvement both subjectively (dry eye symptom score) and objectively (ocular staining score and tear function tests) for aqueous-deficient dry eye.


Diquafosol Dry eye Treatment Tear film 


  1. 1.
    Epidemiology Subcommittee of the International Dry Eye WorkShop. Report of the Epidemiology Subcommittee of the International Dry Eye Work Shop: the epidemiology of dry eye disease. Ocul Surf. 2007; 5:93–07.Google Scholar
  2. 2.
    Mizuno Y, Yamada M, Miyake Y, Dry Eye Survey Group of the National Hospital Organization of Japan. Association between clinical diagnostic tests and health-related quality of life surveys in patients with dry eye syndrome. Jpn J Ophthalmol. 2010;54:259–65.CrossRefPubMedGoogle Scholar
  3. 3.
    Report of the Definition and Classification Subcommittee of the International Dry Eye Work Shop: the definition and classification of dry eye disease. Ocul Surf. 2007; 5:75–92.Google Scholar
  4. 4.
    Li Y, Kuang K, Yerxa B, Wen Q, Rosskothen H, Fischbarg J. Rabbit conjunctival epithelium transports fluid, and P2Y2 receptor agonists stimulate Cl- and fluid secretion. Am J Physiol Cell Physiol. 2001;281:C595–602.PubMedGoogle Scholar
  5. 5.
    Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res. 1998;67:341–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net cl- transport through p2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res. 2004;36:89–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K. Improvement of corneal barrier function by the p2Y(2) agonist iNS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001;42:96–100.PubMedGoogle Scholar
  8. 8.
    Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 2002;18:363–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23:784–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. The efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119:1954–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang J, Aquavella J, Palakuru J, Chung S. Repeated measurements of dynamic tear distribution on the ocular surface after instillation of artificial tears. Invest Ophthalmol Vis Sci. 2006;47:3325–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang J, Aquavella J, Palakuru J, Chung S, Feng C. Relationships between central tear film thickness and tear menisci of the upper and lower eyelids. Invest Ophthalmol Vis Sci. 2006;47:4349–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen Q, Zhang X, Cui L, Huang Q, Chen W, Ma H, et al. Upper and lower tear menisci in Sjögren’s syndrome dry eye. Invest Ophthalmol Vis Sci. 2011;52:9373–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Ibrahim OM, Dogru M, Takano Y, Satake Y, Wakamatsu TH, Fukagawa K, et al. Application of Visante optical coherence tomography tear meniscus height measurement in the diagnosis of dry eye disease. Ophthalmology. 2010;117:1923–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang Y, Zhuang H, Xu J, Wang X, Jiang C, Sun X. Dynamic changes in the lower tear meniscus after instillation of artificial tears. Cornea. 2010;29:404–8.PubMedGoogle Scholar
  16. 16.
    Koh S, Tung C, Aquavella J, Yadav R, Zavislan J, Yoon G. Simultaneous measurement of tear film dynamics using wavefront sensor and optical coherence tomography. Invest Ophthalmol Vis Sci. 2010;51:3441–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Tung CI, Kottaiyan R, Koh S, Wang Q, Yoon G, Zavislan JM, et al. Non-invasive, objective, multimodal tear dynamics evaluation of five over-the-counter tear drops in a randomized, controlled trial. Cornea. 2012;31:108–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Koh S, Tung C, Kottaiyan R, Zavislan J, Yoon G, Aquavella J. Effect of airflow exposure on the tear meniscus. J Ophthalmol. 2012;983182. doi:10.1155/2012/983182.
  19. 19.
    Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjogren’s syndrome (1999): availability and validity. Mod Rheumatol. 2004;14:425–34.CrossRefGoogle Scholar
  20. 20.
    Shimazaki J. Definition and diagnosis of dry eye 2006 (in Japanese). Atarashii Ganka. 2007; 24:181–4.Google Scholar
  21. 21.
    van Bijsterveld OP. Diagnostic tests in the sicca syndrome. Arch Ophthalmol. 1969;82:10–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Amano S. Definition and diagnositic criteria for meibomian gland dysfuncion (in Japanese). Atarashii Ganka. 2010; 27:627–31.Google Scholar
  23. 23.
    Lemp MA. Report of the National Eye Institute/industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221–32.PubMedGoogle Scholar
  24. 24.
    Koh S, Watanabe H, Hosohata J, Hori Y, Hibino S, Nishida K, et al. Diagnosing dry eye using a blue-free barrier filter. Am J Ophthalmol. 2003;136:513–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Yasuno Y, Madjarova VD, Makita S, Akiba M, Morosawa A, Chong C, et al. Three-dimensional and high-speed swept-source optical coherence tomography for in vivo investigation of human anterior eye segments. Opt Express. 2005;13:10652–64.CrossRefPubMedGoogle Scholar
  26. 26.
    Kawana K, Kiuchi T, Yasuno Y, Oshika T. Evaluation of trabeculectomy blebs using 3-dimensional cornea and anterior segment optical coherence tomography. Ophthalmology. 2009;116:848–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Fukuda S, Kawana K, Yasuno Y, Oshika T. Anterior ocular biometry using 3-dimensional optical coherence tomography. Ophthalmology. 2009;116:882–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Wakamatsu TH, Sato EA, Matsumoto Y, Ibrahim OM, Dogru M, Kaido M, et al. Conjunctival in vivo confocal scanning laser microscopy in patients with Sjögren syndrome. Invest Ophthalmol Vis Sci. 2011;51:144–50.CrossRefGoogle Scholar
  29. 29.
    Takaoka-Shichijo Y, Murakami T, Nakamura M. Stimulatory effect of diquafosol tetrasodium on tear fluid secretion in normal rabbit (in Japanese). J Eye. 2011; 28:1029–33.Google Scholar
  30. 30.
    Cowlen MS, Zhang VZ, Warnock L, Moyer CF, Peterson WM, Yerxa BR. Localization of ocular P2Y2 receptor gene expression by in situ hybridization. Exp Eye Res. 2003;77:77–84.CrossRefPubMedGoogle Scholar
  31. 31.
    Management and Therapy Subcommittee of the International Dry Eye WorkShop. Report of the Management and Therapy Subcommittee of the International Dry Eye Work Shop: management and therapy of dry eye disease. Ocul Surf. 2007; 5:163–78.Google Scholar
  32. 32.
    Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004;23:762–70.CrossRefPubMedGoogle Scholar
  33. 33.
    Uchino M, Dogru M, Yagi Y, Goto E, Tomita M, Kon T, et al. The features of dry eye disease in a Japanese elderly population. Optom Vis Sci. 2006;83:797–802.CrossRefPubMedGoogle Scholar
  34. 34.
    Arita R, Itoh K, Maeda S, Maeda K, Tomidokoro A, Amano S. Efficacy of diagnostic criteria for the differential diagnosis between obstructive meibomian gland dysfunction and aqueous deficiency dry eye. Jpn J Ophthalmol. 2010;54:387–91.CrossRefPubMedGoogle Scholar
  35. 35.
    Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Fukuda S, Kawana K, Yasuno Y, Oshika T. Repeatability and reproducibility of anterior ocular biometric measurements with 2-dimensional and 3-dimensional optical coherence tomography. J Cataract Refract Surg. 2010;36:1867–73.CrossRefPubMedGoogle Scholar
  37. 37.
    Fukuda S, Kawana K, Yasuno Y, Oshika T. Repeatability and reproducibility of anterior chamber volume measurements using 3-dimensional corneal and anterior segment optical coherence tomography. J Cataract Refract Surg. 2011;37:461–8.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2013

Authors and Affiliations

  • Shizuka Koh
    • 1
  • Chikako Ikeda
    • 1
  • Yoshihiro Takai
    • 1
  • Hitoshi Watanabe
    • 1
  • Naoyuki Maeda
    • 1
  • Kohji Nishida
    • 1
  1. 1.Department of OphthalmologyOsaka University Graduate School of MedicineSuitaJapan

Personalised recommendations